GSK may move for 51% of Shantha

- Last updated on GMT

UK drug major GSK is considering a bid for a 51 per cent share of India’s Shantha Biotech after European rival Sanofi Aventis pulled out of an acquisition deal last week, according to India’s Economic Times.

The newspaper reported that Sanofi had halted talks with Shantha’s majority shareholder, fellow French group the Merieux Alliance, after deciding the Indian biotech’s pipeline was not an attractive enough proposition.

While neither GlaxoSmithKline (GSK) nor the Merieux Alliance have issued a comment, the paper suggests that a deal would help the UK firm bolster its vaccine pipeline through the addition of Shantha’s penatvalents range.

Related news

Show more